FMP
Sol-Gel Technologies Ltd.
SLGL
NASDAQ
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
0.857 USD
-0.0877 (-10.23%)
About
ceo
Dr. Alon Seri-Levy
sector
Healthcare
industry
Biotechnology
website
https://www.sol-gel.com
exchange
NASDAQ
Description
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and othe...
CIK
0001684693
ISIN
IL0011417206
CUSIP
M8694L103
Address
7 Golda Meir Street
Phone
972 8 931 3433
Country
IL
Employee
36
IPO Date
Feb 1, 2018
Summary
CIK
0001684693
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
M8694L103
ISIN
IL0011417206
Country
IL
Price
0.86
Beta
1.32
Volume Avg.
32.05k
Market Cap
23.87M
Shares
-
52-Week
0.79-4.2
DCF
0.06
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.85
P/B
-
Website
https://www.sol-gel.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SLGL News
It looks like there's no news available.
